In the published article, there was an operator error in the western blot images of Figure 5. The original images provided by the authors were not spliced. The corrected Figure 5 and its caption “UCHL5 activated Wnt/β-catenin signaling and affected the expression of its target genes. (A) Relative protein levels of UCHL5 and β-catenin were detected by WB in HCE-1-A cells at 48 h after shRNA lentiviral infection (N = 3 times). *P < 0.05 vs. sh-NC. (B) Relative levels of cell cycle–related protein CyclinD1 and cell proliferation-related protein C-myc. (N = 3 times). *P < 0.05 vs. sh-NC. (C) Relative levels of cell apoptosis-related protein cleaved-caspase3 and anti-apoptosis protein Survivin (N = 3 times). *P < 0.05 vs. sh-NC. (D) Relative protein levels of UCHL5 and β-catenin were detected by WB in AN3-CA cells at 48 h after infected with overexpressed lentiviral vectors (N = 3 times). *P < 0.05 vs. empty vector. (E) Relative levels of CyclinD1 and C-myc (N = 3 times). *P < 0.05 vs. empty vector. (F) Relative levels of cleaved-caspase3 and Survivin (N = 3 times). *P < 0.05 vs. empty vector.” appear below.
Figure 5
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
endometrial cancer, UCHL5, lentivirus vectors, Wnt/β-catenin pathway, XAV939
Citation
Liu D, Song Z, Wang X and Ouyang L (2022) Corrigendum: Ubiquitin C-Terminal hydrolase L5 (UCHL5) accelerates the growth of endometrial cancer via activating the Wnt/β-catenin signaling pathway. Front. Oncol. 12:992496. doi: 10.3389/fonc.2022.992496
Received
12 July 2022
Accepted
02 August 2022
Published
17 August 2022
Volume
12 - 2022
Edited and reviewed by
Alberto Farolfi, Scientific Institute of Romagna for the Study and Treatment of Tumors (IRCCS), Italy
Updates
Copyright
© 2022 Liu, Song, Wang and Ouyang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ling Ouyang, ouyl@sj-hospital.org
This article was submitted to Women's Cancer, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.